Stephen Poor
Head of Translational Medicine Apellis Pharmaceuticals
Physician-scientist (UK-trained Ophthalmologist) with over 20 years of Biotech drug discovery and drug development. Current role is Head of Translational Medicine at Apellis Pharmaceuticals,
Seminars
Wednesday 25th March 2026
Roundtable Discussion: Designing Flexible Trials to Withstand Changing Biomarker Expectations
3:30 pm
- Identifying intermediate endpoints that could bridge the gap between early biomarker data and long-term clinical outcomes
- Evaluating the unique implications for rare disease programs where long-term outcomes are harder to measure
- Anticipating the impact of a move toward clinical outcome-based approvals on development timelines and investment strategies
